Literature DB >> 15099312

European Consensus Meeting on Foam Sclerotherapy, April, 4-6, 2003, Tegernsee, Germany.

Franz-Xaver Breu1, Stephan Guggenbichler.   

Abstract

BACKGROUND: The introduction of sclerotherapy using foam sclerosants has revitalized interest in this method of treating varicose veins. Foam is made from detergent-type sclerosants already established as safe and effective in conventional liquid sclerotherapy.
OBJECTIVE: European experts in foam sclerotherapy were invited to exchange their opinions and to work on consensus statements and recommendations.
METHODS: A questionnaire covering different areas of foam sclerotherapy was sent to experts who have published or presented data, participated in clinical trials, or otherwise contributed to sclerotherapy with extemporary (self-made) foam. Based on the answers, several consensus statements and recommendations were approved during the consensus meeting.
RESULTS: The use of sclerosing foam is an appropriate procedure in the treatment of varicose veins. It is a powerful tool in the hands of an expert who has sufficient experience in sclerotherapy. Sclerosing foam is more powerful than liquid. Most recommendations for conventional liquid sclerotherapy also apply to foam sclerotherapy. Some differences between these two treatments were highlighted.
CONCLUSION: Foam sclerotherapy is a variation of a well-established treatment that improves varicose vein management. European experts came together to harmonize their opinions about sclerosing foam. The final document reflects the experts' opinion with the aim of defining principles for a safe and effective use of sclerosing foam and for its practical application. Foam sclerotherapy allows a skilled practitioner to treat larger veins including saphenous trunks.

Mesh:

Substances:

Year:  2004        PMID: 15099312     DOI: 10.1111/j.1524-4725.2004.30209.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  15 in total

Review 1.  [Sclerotherapy for varicosities].

Authors:  F Pannier; E Rabe
Journal:  Hautarzt       Date:  2006-01       Impact factor: 0.751

2.  [Treatment of primary varicosis].

Authors:  T Noppeney; H Nüllen
Journal:  Internist (Berl)       Date:  2010-03       Impact factor: 0.743

Review 3.  [Specific indications for foam sclerotherapy].

Authors:  B Kahle
Journal:  Hautarzt       Date:  2017-08       Impact factor: 0.751

Review 4.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

5.  Compression sclerotherapy for primary valvular insufficiency -from liquid to foam-.

Authors:  Takashi Yamaki
Journal:  Ann Vasc Dis       Date:  2010-07-21

6.  A 1470-nm laser combined with foam sclerotherapy in day surgery: a better choice for lower limb varicose veins.

Authors:  Xing Zhang; Xin Wang; Cheng Gao; Jinbao Qin; Haiguang Zhao; Weimin Li; Xinwu Lu
Journal:  Lasers Med Sci       Date:  2018-04-23       Impact factor: 3.161

7.  Foam sclerotherapy using polidocanol for balloon-occluded retrograde transvenous obliteration (BRTO).

Authors:  Sun Young Choi; Jong Yun Won; Kyung Ah Kim; Do Yun Lee; Kwang-Hun Lee
Journal:  Eur Radiol       Date:  2010-08-26       Impact factor: 5.315

8.  Current treatment of varicose veins.

Authors:  François Becker
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-04

9.  Treatment of varicose veins.

Authors:  Raha Nael; Suman Rathbun
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-04

10.  Fluoroscopy-guided endovenous sclerotherapy using a microcatheter prior to endovenous laser ablation: comparison between liquid and foam sclerotherapy for varicose tributaries.

Authors:  Sang Woo Park; Ik Jin Yun; Jae Joon Hwang; Song Am Lee; Jun Seok Kim; Hyun Keun Chee; Il Soo Chang
Journal:  Korean J Radiol       Date:  2014-07-09       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.